Cargando…

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review

INTRODUCTION: Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We conducted a systematic review to assess the effectiveness and safety of dolutegravir and raltegravir in childr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Townsend, Claire L., O'Rourke, John, Milanzi, Edith, Collins, Intira Jeannie, Judd, Ali, Castro, Hannah, Vicari, Marissa, Jesson, Julie, Leroy, Valériane, Renaud, Françoise, Penazzato, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663860/ https://www.ncbi.nlm.nih.gov/pubmed/36377082 http://dx.doi.org/10.1002/jia2.25970

Ejemplares similares

Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review
por: O'Rourke, John, et al.
Publicado: (2023)

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review
por: Saint-Lary, Laura, et al.
Publicado: (2022)

Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis
por: Jesson, Julie, et al.
Publicado: (2022)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents
por: Ciaranello, Andrea, et al.
Publicado: (2018)

Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
por: Innes, Steve, et al.
Publicado: (2018)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2)
por: Blanco, Jose-Ramon, et al.
Publicado: (2020)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action
por: Penazzato, Martina, et al.
Publicado: (2022)

The Brazilian experience of implementing the active pharmacovigilance of dolutegravir
por: Batista, Cynthia Julia Braga, et al.
Publicado: (2019)

Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework
por: Renaud, Françoise, et al.
Publicado: (2022)

It ain’t what you do, it’s the way that you do it: The pitfalls of using routine data to measure early infant HIV diagnosis in HIV-exposed infants
por: Chappell, Elizabeth, et al.
Publicado: (2021)

Effect of in utero exposure to HIV and antiretroviral drugs on growth in HIV-exposed uninfected children: a systematic review and meta-analysis protocol
por: Ekali, Gabriel L, et al.
Publicado: (2019)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Surviving and Thriving—Shifting the Public Health Response to HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child Workshop
por: Slogrove, Amy L., et al.
Publicado: (2018)

Immediate antiretroviral therapy in young HIV-infected children: benefits and risks
por: Collins, Intira J., et al.
Publicado: (2014)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
por: Indu, Purushothaman, et al.
Publicado: (2020)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK
por: Judd, Ali, et al.
Publicado: (2017)

Update on Adverse Effects of HIV Integrase Inhibitors
por: Kolakowska, Agnieszka, et al.
Publicado: (2019)

Setting Global Research Priorities in Pediatric and Adolescent HIV Using the Child Health and Nutrition Research Initiative (CHNRI) Methodology
por: Irvine, Cadi, et al.
Publicado: (2018)

Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines
por: Malik, Farihah, et al.
Publicado: (2021)

A Global Research Agenda for Pediatric HIV
por: Penazzato, Martina, et al.
Publicado: (2018)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nuulcl7q37om2gv3vaqghbee4i